Drug shortage
Extended Release · Takeda Pharmaceuticals USA Inc.
FDA drug shortage · To Be Discontinued · updated Sep 16, 2026
Key facts
| Generic name | Extended Release, Mesalamine Capsule |
|---|---|
| Company | Takeda Pharmaceuticals USA Inc. |
| Presentation | Pentasa, Capsule, Extended Release, 500 mg (NDC 54092-191-12) |
| Dosage form | Capsule, Extended Release |
| Status | To Be Discontinued |
| Therapeutic category | Gastroenterology |
| Package NDCs | 54092-191-12 |
| First posted | Sep 16, 2026 |
| Last updated | Sep 16, 2026 |
| Discontinued | Sep 16, 2026 |
At a glance
- 1–9 Package NDCs affected
- 100–999 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: